Ung thư | Medical News

Can SLN mapping replace lymphadenectomy for surgical staging of early-stage EEC?

Audrey Abella, 20240115100000

Researchers from the KK Women’s and Children’s Hospital, Singapore found that sentinel lymph node (SLN) mapping is an acceptable and safe alternative to routine lymphadenectomy in the surgical staging of early-stage endometrioid endometrial cancer (EEC).

Antivirals underutilized after curative resection of HBV- or HCV-related HCC

Christina Lau, 20240115091119

Antiviral therapy is associated with substantial improvements long-term survival overall (OS) but severely underutilized after curative hepatic resection in patients with hepatitis B virus (HBV)– or hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), a real-world study involving predominantly Asian patients has shown.

Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC

Christina Lau, 20240115000000

The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.

Resection plus chemo improves survival in patients with UCR-MAC-LM

Stephen Padilla, 20240114120000

Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.

ChatGPT answers questions about cancer

20240114110000

Artificial intelligence (AI)-powered chatbots can potentially improve healthcare, particularly in answering questions by patients regarding cancer, reveals a recent study.

Maintenance olaparib rechallenge improves PFS in ovarian cancer patients

Stephen Padilla, 20240113120000

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.

Survivors cope with life after testicular cancer

20240113110000

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.

Dr Yasutoshi Kuboki, ESMO Asia 2023, CodeBreak 300

CodeBreaK 300: Sotorasib + panitumumab prolongs PFS in metastatic colorectal cancer

Elaine Soliven, 20240113000000

Adding sotorasib to panitumumab significantly improves progression-free survival (PFS) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with investigator’s choice of standard of care treatment, according to the CodeBreaK 300 trial presented at ESMO Asia 2023.

Sacituzumab govitecan confers survival benefit in Asian patients with mBC

Elaine Soliven, 20240112150000

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women

Jairia Dela Cruz, 20240111140000

Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.